Multiple treatments with human embryonic stem cell-derived mesenchymal progenitor cells preserved the fertility and ovarian function of perimenopausal mice undergoing natural aging

Eun-Young Shin,Suji Jeong,Jeoung Eun Lee,Dong Seok Jeong,Dong Keun Han,Seok-Ho Hong,Dong Ryul Lee

DOI: https://doi.org/10.1186/s13287-024-03684-6

2024-03-05

Stem Cell Research & Therapy

Abstract:Currently, no approved stem cell-based therapies for preserving ovarian function during aging. To solve this problem, we developed a long-term treatment for human embryonic stem cell-derived mesenchymal progenitor cells (hESC-MPCs). We investigated whether the cells retained their ability to resist ovarian aging, which leads to delayed reproductive senescence.

cell biology,medicine, research & experimental,cell & tissue engineering

What problem does this paper attempt to address?

The problem that this paper attempts to solve is: **There are currently no approved stem - cell - based therapies for maintaining ovarian function during the aging process.**

Specifically, as women age, their ovarian function gradually declines, leading to a decrease in reproductive ability and an increase in menopausal - related health problems. To meet this challenge, researchers have developed a long - term treatment protocol using human embryonic stem cell - derived mesenchymal progenitor cells (hESC - MPCs) to evaluate whether these cells can resist ovarian aging and delay reproductive aging.

### Main research objectives of the paper:
1. **Evaluate the long - term maintenance effect of hESC - MPCs on ovarian function**: The research team hopes to maintain the reproductive ability of middle - aged female mice through multiple injections of hESC - MPCs and explore how their transplantation regulates ovarian function.
2. **Explore the impact of hESC - MPCs on ovarian fibrosis**: The study also examined whether hESC - MPCs can reduce ovarian fibrosis by suppressing the expression of inflammation - and fibrosis - related genes.
3. **Verify the improvement effect of hESC - MPCs on reproductive outcomes**: The research team further evaluated the impact of hESC - MPCs on pregnancy outcomes, including parameters such as mating rate, delivery rate, number of offspring, and litter size.

Through these studies, the authors hope to find an effective method to use hESC - MPCs to delay ovarian aging, maintain fertility, and provide a theoretical basis for future clinical applications.

### Key concepts and methods involved:
- **hESC - MPCs**: Mesenchymal progenitor cells derived from human embryonic stem cells, with high proliferation ability and easy standardization characteristics.
- **Ovarian function**: It includes follicle reserve, hormone secretion (such as estradiol), and the regularity of the reproductive cycle.
- **Ovarian fibrosis**: A pathological change related to aging that affects the ovarian structure and function.
- **Experimental model**: Use a naturally aging middle - aged female mouse model for research.
- **Multiple injections**: Evaluate the effect of long - term treatment through monthly intravenous injections.

### Research results:
- hESC - MPCs significantly increased the number of primordial follicles, restored estradiol levels, and increased the proportion of normal reproductive cycles.
- hESC - MPCs reduced ovarian fibrosis and inhibited age - related inflammatory responses.
- hESC - MPCs improved egg quality and embryo development, and increased pregnancy and live birth rates.

In conclusion, this study aims to develop an effective stem - cell therapy to delay ovarian aging and maintain the fertility of middle - aged women.